SRRK - スカラ―・ロック・ホ―ルディング (Scholar Rock Holding Corporation) スカラ―・ロック・ホ―ルディング

 SRRKのチャート


 SRRKの企業情報

symbol SRRK
会社名 Scholar Rock Holding Corp (スカラ―・ロック・ホ―ルディング)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 医薬品   医療関連(Health Care)
概要 事業概要 スカラー・ロック・ホールディング(Scholar Rock Holding Corporation)は生物医薬品企業である。同社は、神経筋障害、癌、線維症および貧血などの疾患の治療用モノクローナル抗体の開発に従事する。同社のリード製品候補は、開発の前臨床段階にあるSRK-015である。SRK-015は骨格筋における成長因子ミオスタチンの活性化の選択的阻害剤であり、脊髄性筋萎縮症(SMA)の治療に使用される。同社はまた、TGFβ1およびBMP6を含む他の抗体プログラムを開発する。TGFβ1抗体プログラムはTGFβ1メンバーの特異的阻害剤である抗体の開発を中心とする。   スカラ―・ロック・ホ―ルディングは米国のバイオ医薬品系持株会社。子会社を通じ、神経筋疾患、がん、線維症、貧血などを含む重篤疾患を治療するための新薬の発見、開発に従事する。同社の主力製品は脊髄性筋萎縮症患者の治療用に開発されたSRK-015。本社所在地はマサチュ―セッツ州ケンブリッジ。   Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock's approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.
本社所在地 620 Memorial Drive 2nd Floor Cambridge MA 02139 USA
代表者氏名 David L. Hallal デイビッド・L・ハラル
代表者役職名 Independent Chairman of the Board
電話番号 +1 857-259-3860
設立年月日 2017年
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 50人
url www.scholarrock.com
nasdaq_url https://www.nasdaq.com/symbol/srrk
adr_tso
EBITDA EBITDA(百万ドル) -37.60200
終値(lastsale) 22.01
時価総額(marketcap) 555613484.84
時価総額 時価総額(百万ドル) 526.58330
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 412.25330
当期純利益 当期純利益(百万ドル) -37.98500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Scholar Rock Holding Corp revenues was not reported. Net loss increased from $10.6M to $23.6M. Higher net loss reflects Research and development - Balancing val increase from $5.7M to $13M (expense) General and administrative - Balancing v increase from $4.5M to $9.4M (expense) Stock-based Compensation in R&D increase from $226K to $787K (expense).

 SRRKのテクニカル分析


 SRRKのニュース

   Scholar Rock climbs on Phase 2 data for spinal muscular atrophy therapy  2021/06/11 17:19:02 Seeking Alpha
   Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting  2021/06/07 00:00:00 BioSpace
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced an oral presentation of apitegromab TOPAZ Phase 2 clinical trial results at the 2021 Virtual SMA Research and Clinical Care Meeting, being held in conjunction with Cure SMAs Annual SMA Conference June 7-11, 2021.
   Scholar Rock to Present at Upcoming Healthcare Conferences in June  2021/05/27 00:00:00 BioSpace
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences: Jefferies Virtual Healthcare Conference on Wednesday, June 2 nd , 2021 at 11:00 a.m. ET.
   Scholar Rock''s apitegromab gets Fast Track designation; shares up 9% after-hours  2021/05/24 20:22:26 Seeking Alpha
   Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy  2021/05/24 00:00:00 BioSpace
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for apitegromab
   Scholar Rock Announces Senior Management Promotions  2021/02/04 21:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that its Board of Directors has approved several promotions within the senior management team, including Gregory Carven, Ph.D. to Chief Scientific Officer, Junlin Ho, J.D. to General Counsel and Corporate Secretary, and George Nomikos, M.D., Ph.D. to Senior Vice President,
   Scholar Rock Presents Preclinical Data for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit  2021/01/27 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced a presentation at the 2021 TGFβ for Immuno-Oncology Drug Development Summit. “Inhibition of TGFβ1 Activation with SRK-181 Overcomes Primary Resistance to Checkpoint Inhibition Therapy” will be presented on January 28th, 2021 at 12:30 PM EST. The presentation will provide an
   Scholar Rock Provides Corporate Update and Highlights Priorities for 2021  2021/01/11 12:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today provided a corporate update and highlighted priorities for 2021. “2020 was a transformative year for Scholar Rock with significant progress made both clinically and operationally with positive interim data from the TOPAZ trial providing initial proof-of-concept of apitegromab’s poten
   Scholar Rock to Present at the 39th Annual J.P. Morgan Healthcare Conference  2021/01/04 21:01:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 5:20 p.m. ET. A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.sc
   Scholar Rock Reports Third Quarter 2020 Financial Results and Highlights Business Progress  2020/11/09 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results for the third quarter ended September 30, 2020 and highlighted recent progress and upcoming milestones for its pipeline programs. “We achieved a significant milestone with the TOPAZ interim analysis proof-of-concept results. The data support apitegromab’s p
   Scholar Rock Announces Senior Management Promotions  2021/02/04 21:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that its Board of Directors has approved several promotions within the senior management team, including Gregory Carven, Ph.D. to Chief Scientific Officer, Junlin Ho, J.D. to General Counsel and Corporate Secretary, and George Nomikos, M.D., Ph.D. to Senior Vice President,
   Scholar Rock Presents Preclinical Data for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit  2021/01/27 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced a presentation at the 2021 TGFβ for Immuno-Oncology Drug Development Summit. “Inhibition of TGFβ1 Activation with SRK-181 Overcomes Primary Resistance to Checkpoint Inhibition Therapy” will be presented on January 28th, 2021 at 12:30 PM EST. The presentation will provide an
   Scholar Rock Provides Corporate Update and Highlights Priorities for 2021  2021/01/11 12:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today provided a corporate update and highlighted priorities for 2021. “2020 was a transformative year for Scholar Rock with significant progress made both clinically and operationally with positive interim data from the TOPAZ trial providing initial proof-of-concept of apitegromab’s poten
   Scholar Rock to Present at the 39th Annual J.P. Morgan Healthcare Conference  2021/01/04 21:01:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 5:20 p.m. ET. A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.sc
   Scholar Rock Reports Third Quarter 2020 Financial Results and Highlights Business Progress  2020/11/09 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results for the third quarter ended September 30, 2020 and highlighted recent progress and upcoming milestones for its pipeline programs. “We achieved a significant milestone with the TOPAZ interim analysis proof-of-concept results. The data support apitegromab’s p

 関連キーワード  (医薬品 米国株 スカラ―・ロック・ホ―ルディング SRRK Scholar Rock Holding Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)